Idogen Q1’22: Trial About to Commence - Redeye

Redeye leaves its comments on Idogen following the report for the first quarter of 2022. Company operations are centered around phase l/lla-trial start, and patient enrollment in Sweden is estimated to commence mid-year. Meanwhile, the share is currently trading at a single-digit EV.

Länk till analysen i sin helhet: https://www.redeye.se/research/840465/idogen-q122-trial-about-to-commence?utm_source=finwire&utm_medium=RSS